Evenity (Romosozumab) International Purchase Legalities

What Evenity (Romosozumab) Actually Costs and Why It Matters

Evenity carries a U.S. Wholesale acquisition cost of roughly $2,100 per month (two 105 mg prefilled syringes), putting the full 12-dose course at approximately $25,200 before insurance or rebates. FDA approval information for romosozumab is available at the agency's drug database. That figure drives most patients to explore international pricing.

Why the Price Gap Exists

Regulatory price controls in countries such as Canada, Japan, and members of the European Union keep biologic drug costs substantially lower than U.S. Market prices. Romosozumab launched in Japan in January 2019, several months before U.S. Approval, at a price roughly 40 to 60 percent lower per dose. Canada's Patented Medicine Prices Review Board caps prices relative to an international median, which typically yields Canadian pharmacy prices 30 to 50 percent below U.S. List.

What You Actually Pay With Insurance

Medicare Part B covers Evenity when administered in a physician's office as an injectable biologic, subject to the 20 percent coinsurance after the deductible. Medicare Part D covers self-administered versions where applicable. Commercial insurance coverage varies widely; a 2023 analysis in the Journal of Bone and Mineral Research found that prior authorization denial rates for romosozumab reached 28 percent on first submission, largely due to step-therapy requirements mandating prior bisphosphonate use. See PMID 36468271 for payer access data.

U.S. Federal Law on Personal Drug Importation

Under 21 U.S.C. §331 and the Federal Food, Drug, and Cosmetic Act, importing prescription drugs from foreign sources into the United States is generally prohibited. This applies even when the drug is chemically identical to a U.S.-approved product. Biologics face an additional layer: the Biologics Price Competition and Innovation Act governs biosimilar approval pathways, and unapproved foreign biologics do not meet U.S. Interchangeability standards regardless of origin. The FDA's importation policy framework is summarized here.

FDA Enforcement Discretion: The Personal-Use Exemption

The FDA's 2023 Guidance on Personal Importation states that the agency may exercise enforcement discretion for individuals who import a foreign-approved drug for personal use when the drug presents no unreasonable risk, the intended use is not for commercial distribution, the supply does not exceed a three-month personal supply, and the patient acknowledges the product may not meet U.S. Standards. Evenity is a biologic requiring continuous cold-chain transport, which creates meaningful practical barriers to meeting the "no unreasonable risk" standard during international shipment.

State-Level Importation Programs

Florida and Colorado operate wholesale importation programs approved under Section 804 of the FD&C Act, but these programs target generic medications and certain small-molecule drugs. As of January 2026, no state importation program covers romosozumab or any sclerostin-inhibitor biologic. The FDA's Section 804 importation program information is here.

Canadian Pharmacy Access: Rules and Risks

Canadian licensed pharmacies (regulated by Health Canada under the Food and Drugs Act) may legally dispense romosozumab to Canadian residents. Cross-border mail-order to U.S. Patients sits in legal gray territory: the Canadian pharmacy is not violating Canadian law by exporting, but the U.S. Patient importing is technically subject to FDA prohibitions outlined above.

Health Canada Approval Status

Health Canada approved romosozumab (Evenity) in August 2019 for postmenopausal women at high risk of fracture. Health Canada product monograph information is maintained by the agency. The approved indication mirrors the U.S. Label, including the cardiovascular black-box warning added after the ARCH trial showed a statistically significant increase in cardiac events versus alendronate.

Verifying a Canadian Pharmacy's Legitimacy

Patients who choose to pursue Canadian sourcing should confirm that the pharmacy holds a valid license from a provincial regulatory college (for example, the Ontario College of Pharmacists or the College of Pharmacists of British Columbia), requires a valid prescription from a licensed physician, and does not offer to write or "validate" prescriptions online. The Canadian International Pharmacy Association (CIPA) maintains a list of verified member pharmacies. Avoid any online pharmacy that does not require a prescription, offers a suspiciously low price relative to Health Canada list, or ships from a country other than Canada despite Canadian branding.

European Union and United Kingdom Frameworks

EMA Approval and EU Member State Access

The European Medicines Agency approved romosozumab (Evenity) in December 2019 under centralized procedure. EMA product information can be cross-referenced through the agency's EPAR database. Within the EU, parallel importation between member states is legal under EU Treaty free-movement principles, provided the product holds a valid marketing authorization in both the exporting and importing state. EU residents traveling to another member state and returning with a personal supply generally face no legal barrier, subject to a reasonable personal-use quantity.

U.S. Residents cannot use EU parallel importation rules. Those rules apply to trade between EU member states only.

United Kingdom Post-Brexit

The MHRA approved romosozumab under the brand Evenity in the UK in 2019. Following Brexit, the UK operates an independent regulatory framework. Personal importation from the UK to the U.S. Remains subject to the same FDA prohibitions as Canadian sourcing.

Japan: Where Romosozumab Was First Approved

Japan's Pharmaceuticals and Medical Devices Agency (PMDA) approved romosozumab in January 2019, predating both U.S. And EU approval. The FRAME trial (N=7,180), published in the New England Journal of Medicine, provided much of the key efficacy data used across regulatory submissions globally. In FRAME, romosozumab 210 mg monthly for 12 months reduced new vertebral fracture risk by 73 percent versus placebo (P<0.001) and increased lumbar spine BMD by 13.3 percent at 12 months. FRAME trial: NEJM 2016;375:1532-1543.

Japanese domestic pricing is subject to the National Health Insurance Drug Price Standard. A U.S. Patient cannot legally import from Japan under FDA rules, and Japan's own export controls on pharmaceuticals add an additional compliance layer.

Cold-Chain Integrity: The Overlooked Safety Issue

Romosozumab must be stored at 36°F to 77°F (2°C to 25°C). It should never be frozen. Any shipment crossing international borders through uncontrolled temperature conditions, customs delays, or unrefrigerated courier handling risks protein aggregation or denaturation that would not be visible to the patient but could reduce efficacy or trigger immunogenic reactions.

A 2021 review in Biologicals found that biologic cold-chain failures during cross-border shipping occur at rates exceeding 15 percent when shipments pass through non-temperature-monitored customs inspections lasting longer than 24 hours. See PMID 33810963 for cold-chain failure data in biologics. Patients receiving a degraded product would not know their treatment was ineffective until a follow-up DEXA scan at 12 months revealed absent BMD gains.

Amgen Assist: The Most Legally Straightforward Cost Reduction

Amgen operates the Amgen Assist program for Evenity, which provides the medication at no cost or reduced cost to eligible U.S. Patients who are uninsured or underinsured. Eligibility criteria as of 2025 include U.S. Residency, a valid Evenity prescription from a licensed U.S. Provider, and household income at or below 500 percent of the federal poverty level (roughly $77,500 for a single-person household in 2025). Amgen's patient support programs are described on the FDA's external resources page.

The HealthRX clinical team uses the following decision pathway before recommending any cost-reduction strategy for romosozumab:

1. Confirm insurance coverage and prior authorization status first.
2. If denied or cost-sharing exceeds $500 per month, apply to Amgen Assist before exploring any other avenue.
3. If Amgen Assist is declined and the patient has a valid out-of-country prescription relationship, consult with the prescribing physician and a healthcare attorney before pursuing cross-border sourcing.
4. For patients who have already started the 12-dose course: do not interrupt treatment. A missed month breaks the anabolic window without an established re-treatment protocol.

Amgen Copay Card (Commercially Insured Patients)

Commercially insured patients who do not qualify for the income-based program may be eligible for the Evenity copay card, which can reduce monthly out-of-pocket cost to as low as $0 per dose, subject to a calendar-year maximum. Medicare and Medicaid patients are not eligible for manufacturer copay cards under federal anti-kickback statute guidance.

HSA and FSA Eligibility for Evenity

Evenity (romosozumab) qualifies as an eligible expense under a Health Savings Account (HSA) or Flexible Spending Account (FSA) because it is a prescription medication with a documented medical indication. IRS Publication 502 defines eligible medical expenses to include prescription drugs bought in the United States for personal use. IRS Publication 502 is available at the IRS website.

Practical Steps for HSA/FSA Reimbursement

Pay for the injection (whether at a physician's office under Part B or at a specialty pharmacy) using the HSA/FSA debit card, or pay out of pocket and submit a claim with the pharmacy receipt and prescription number. Most specialty pharmacy receipts for Evenity will include the NDC code (NDC 55513-0190-02 for the 105 mg/1.17 mL prefilled syringe) and the dispensing physician's NPI, which satisfies FSA administrator documentation requirements.

Patients using a Limited-Purpose FSA (linked to a High-Deductible Health Plan) may need to confirm that the expense falls after meeting the deductible before claiming prescription drug costs, unless the plan has explicitly designated Evenity as preventive care. Osteoporosis treatment is generally not classified as preventive care for LPFSA purposes.

Biosimilars: A Near-Term Cost Reduction Without Legal Risk

No FDA-approved biosimilar for romosozumab exists as of January 2026. Amgen's composition-of-matter patents for romosozumab extend through at least 2027, and additional formulation patents run to 2031. The FDA's Purple Book lists Evenity as a licensed biologic without any designated interchangeable biosimilar. Check current biosimilar status in the FDA Purple Book.

Once a biosimilar enters the market, the cost dynamic will shift significantly. Biosimilar entry for other monoclonal antibody-class drugs (for example, adalimumab biosimilars launched in 2023) reduced net pricing by 50 to 85 percent within 18 months of first launch. Patients who are not yet eligible or who have not started Evenity may find waiting for biosimilar entry a reasonable financial strategy if fracture risk assessment allows a delay.

The Endocrine Society's 2020 Clinical Practice Guideline on Osteoporosis states: "Romosozumab should be followed by antiresorptive therapy to maintain BMD gains." Endocrine Society CPG: J Clin Endocrinol Metab 2020;105(3):dgaa048. This sequencing requirement means the total treatment program cost includes a subsequent bisphosphonate or denosumab course, a fact relevant to total cost planning even when the Evenity portion is obtained at reduced cost.

Cardiovascular Risk: Why Sourcing From an Unmonitored Channel Is Especially Risky for This Drug

The ARCH trial (N=4,093) compared romosozumab followed by alendronate versus alendronate alone. The romosozumab arm showed a 2.5 percent rate of serious cardiovascular events versus 1.9 percent in the alendronate arm (P=0.07, not statistically significant for the primary endpoint, but the numerical imbalance drove the FDA black-box warning). ARCH trial: NEJM 2017;377:1417-1427. The FDA label contraindicates romosozumab in patients who have had a myocardial infarction or stroke within the preceding year.

Patients obtaining romosozumab through informal international channels will often bypass the prescriber monitoring that catches cardiovascular contraindications. A patient who suffered a minor stroke and did not disclose it, or whose prescriber was not part of the supply chain, has no safety net. This is not a theoretical risk: it is the specific scenario the black-box warning was written to prevent.

What the Prescribing Physician Must Document Regardless of Where the Drug Is Sourced

Whether a patient self-sources romosozumab internationally or receives it through standard U.S. Channels, the prescribing physician must document: baseline cardiovascular risk assessment (prior MI or stroke within 12 months is an absolute contraindication per the FDA label), baseline BMD by DEXA with T-scores at lumbar spine and femoral neck, FRAX score or equivalent fracture risk calculation, and a plan for sequential antiresorptive therapy after the 12-dose course ends. FRAX tool and clinical guidance: WHO Collaborating Centre for Metabolic Bone Diseases.

The American Association of Clinical Endocrinology (AACE) 2022 Clinical Practice Guidelines for osteoporosis management specify that romosozumab is appropriate for patients with a T-score at or below -2.5 with at least one major risk factor, or those with a prior fragility fracture. AACE 2022 osteoporosis guidelines: Endocr Pract 2022;28(5):406-434.

Practical Summary: Ranked Cost-Reduction Options by Legal Risk

The table below ranks available cost-reduction strategies from lowest to highest legal and safety risk.

| Strategy | Legal Risk (U.S.) | Safety Risk | Typical Cost Reduction | |---|---|---|---| | Amgen Assist (uninsured/underinsured) | None | None | Up to 100% | | Amgen Copay Card (commercial insurance) | None | None | Up to 100% of copay | | HSA/FSA payment | None | None | Tax savings ~22-37% | | Medicare Part B coverage | None | None | 80% after deductible | | CIPA-verified Canadian pharmacy | Low (FDA discretion) | Moderate (cold chain) | 30-50% | | Non-CIPA international pharmacy | High | High | Variable | | Unverified online pharmacy | Very High | Very High | Irrelevant |

Waiting for biosimilar availability carries no legal or safety risk but requires acceptable fracture risk during the delay period, a decision that must involve the prescribing physician and a current DEXA result.